PE20100747A1 - Compuestos heterociclicos como inhibidores de mek - Google Patents
Compuestos heterociclicos como inhibidores de mekInfo
- Publication number
- PE20100747A1 PE20100747A1 PE2009000543A PE2009000543A PE20100747A1 PE 20100747 A1 PE20100747 A1 PE 20100747A1 PE 2009000543 A PE2009000543 A PE 2009000543A PE 2009000543 A PE2009000543 A PE 2009000543A PE 20100747 A1 PE20100747 A1 PE 20100747A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- heterocyclic compounds
- compounds
- indolizin
- bromo
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title 1
- -1 4-BROMO-2-FLUORO-PHENYL-AMINO Chemical class 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101000790711 Chlamydomonas reinhardtii Uncharacterized membrane protein ycf78 Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE X ES ALQUILENO(C1-C3), -N(R6)-, -O- O -S(O)p-, DONDE p ES DE 0 A 2; R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, CN, ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO(C1-C6), ALCOXILO(C1-C6), OH, ENTRE OTROS; R5 ES H, HALOGENO, ALQUILO(C1-C3) O HALOALQUILO(C1-C3); Z ES O O N(R18), DONDE R6 Y R18 SON CADA UNO H O ALQUILO(C1-C6); R26 ES H, ALQUILO(C1-C6), HIDROXIALQUILO(C1-C6), ENTRE OTROS; m Y n SON CADA UNO DE 0 A 3. SON COMPUESTOS PREFERIDOS: ETIL-ESTER DEL ACIDO 7-(4-BROMO-2-FLUORO-FENIL-AMINO)-5-OXO-1,2,3,5-TETRAHIDRO-INDOLIZIN-8-CARBOXILICO, CICLOPROPIL-METOXI-AMIDA DEL ACIDO 7-(4-BROMO-2-FLUORO-FENIL-AMINO)-5-OXO-1,2,3,5-TETRAHIDRO-INDOLIZIN-8-CARBOXILICO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE CINASA MEK SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES HIPERPROLIFERATIVAS COMO CANCER E INFLAMACION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN968CH2008 | 2008-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100747A1 true PE20100747A1 (es) | 2010-11-03 |
Family
ID=40834537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2009000543A PE20100747A1 (es) | 2008-04-21 | 2009-04-20 | Compuestos heterociclicos como inhibidores de mek |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090275606A1 (es) |
| AR (1) | AR071587A1 (es) |
| CL (1) | CL2009000949A1 (es) |
| PE (1) | PE20100747A1 (es) |
| TW (1) | TW201038267A (es) |
| UY (1) | UY31775A (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5453290B2 (ja) * | 2007-11-12 | 2014-03-26 | 武田薬品工業株式会社 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
| JP5466767B2 (ja) * | 2009-11-04 | 2014-04-09 | ノバルティス アーゲー | Ｍｅｋ阻害剤として有用なヘテロ環式スルホンアミド誘導体 |
| WO2011067348A2 (en) * | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| WO2011067356A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Polymorphs of a mek inhibitor |
| CN102020651B (zh) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| CA2890238A1 (en) | 2012-11-02 | 2014-05-08 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN105061283B (zh) * | 2015-08-09 | 2017-11-24 | 浙江大学 | 氨基酸苄酯盐酸盐的制备方法 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002212598A1 (en) * | 2000-09-19 | 2002-04-02 | Centre National De La Recherche Scientifique (Cnrs) | Pyridinone and pyridinethione derivatives having hiv inhibiting properties |
| DK1357111T3 (da) * | 2000-12-28 | 2009-11-02 | Shionogi & Co | 2-pyridonderivater med affinitet for cannabinoid type 2-receptor |
| US20050101590A1 (en) * | 2002-02-19 | 2005-05-12 | Kiyoshi Yasui | Antipruritics |
| US8101799B2 (en) * | 2005-07-21 | 2012-01-24 | Ardea Biosciences | Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK |
| JP5269762B2 (ja) * | 2006-04-18 | 2013-08-21 | アーディア・バイオサイエンシーズ・インコーポレイテッド | Ｍｅｋ阻害剤としてのピリドンスルホンアミドおよびピリドンスルファミド |
| JP5491199B2 (ja) * | 2007-01-19 | 2014-05-14 | アルデア バイオサイエンシズ，インコーポレイティド | Ｍｅｋのインヒビター |
| US20110071125A1 (en) * | 2007-05-11 | 2011-03-24 | Joachim Rudolph | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity |
| JP5453290B2 (ja) * | 2007-11-12 | 2014-03-26 | 武田薬品工業株式会社 | Ｍａｐｋ／ｅｒｋキナーゼ阻害剤 |
-
2009
- 2009-04-20 PE PE2009000543A patent/PE20100747A1/es not_active Application Discontinuation
- 2009-04-20 TW TW098113073A patent/TW201038267A/zh unknown
- 2009-04-20 AR ARP090101381A patent/AR071587A1/es unknown
- 2009-04-20 CL CL2009000949A patent/CL2009000949A1/es unknown
- 2009-04-21 UY UY0001031775A patent/UY31775A/es not_active Application Discontinuation
- 2009-04-21 US US12/427,137 patent/US20090275606A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2009000949A1 (es) | 2010-12-24 |
| UY31775A (es) | 2010-11-30 |
| TW201038267A (en) | 2010-11-01 |
| AR071587A1 (es) | 2010-06-30 |
| US20090275606A1 (en) | 2009-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20100747A1 (es) | Compuestos heterociclicos como inhibidores de mek | |
| PE20110419A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| PE20110153A1 (es) | Derivados de piridazina como inhibidores de smo | |
| PE20110545A1 (es) | Compuestos de triazolopiridina como inhibidores de jak | |
| EA201200174A1 (ru) | Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений | |
| PE20081345A1 (es) | Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico | |
| PE20121500A1 (es) | 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2 | |
| PE20091039A1 (es) | IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10 | |
| PE20120330A1 (es) | Derivados amino-propionicos sustituidos como inhibidores de neprilisina | |
| PE20141004A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20140623A1 (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2 | |
| PE20140192A1 (es) | Derivados de bencimidazol como inhibidores de cinasa pi3 | |
| PE20120632A1 (es) | Inhibidores de bace | |
| PE20121438A1 (es) | Derivados de imidazopiridina o imidazopirimidina como inhibidores de fosfodiesterasa 10a | |
| PE20120061A1 (es) | Derivados de pirimidina como antagonistas del receptor ccr2 | |
| PE20141404A1 (es) | Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas | |
| CR20120053A (es) | Compuestos y metodos inhibidores de jak de pirazolopirimidina | |
| AR077468A1 (es) | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa | |
| PE20160115A1 (es) | Compuestos derivados de imidazol como inhibidores de protein quinasa | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| MY156438A (en) | Substituted isoquinolinones and quinazolinones | |
| EA201200176A1 (ru) | Производные оксазина и их применение для лечения неврологических нарушений | |
| PE20090774A1 (es) | Compuestos heterociclicos como moduladores de la enzima dgat1 | |
| EA201400338A1 (ru) | Производные аминопиримидина для применения в качестве модуляторов киназной активности |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |